Insecticides (India) Limited has informed the Exchange about Transcript
INSECTICID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Insecticides (India) reported strong Q4 FY25 results with revenue growth of ~32% YoY, driven by ~40% volume growth despite an 8% price decline. Full year revenue grew 2% with volume growth of ~10%. Gross margin improved 655 bps to 32% in FY25, EBITDA margin expanded 281 bps to 11.1%, and PAT grew 39% to Rs. 142 crore (up from Rs. 102 crore in FY24). The company launched 12 new products in FY25, with 4 promoted to its 'Focused Maharatna' high-value category. Dahej plant received government approval and will commence production in June 2025, with an expected Rs. 100 crore contribution in FY26. Management reaffirmed double-digit growth guidance and targets 200-300 bps further EBITDA improvement over 2-3 years, driven by premiumization and 6 new launches planned for FY26.
Positive for shareholders — the earnings transcript highlights a clear shift in product mix toward higher-margin premium products, improving profitability metrics, and a strong growth pipeline supported by new launches and capex coming online. Inventory build-up is temporary and tied to the upcoming monsoon season, which management expects to be strong.